



21 OCTOBER, 2022
(FRIDAY)



14:00 - 17:20 HRS
UAE TIME



HYBRID
(IN-PERSON & VIRTUAL)



ALRAS 3

SESSION 1

- Chairperson:** Deborah Mukherji, UAE | Tobias Arkenau, United Kingdom
- 14:00 - 14:10 **Opening Remarks**
Tobias Arkenau, United Kingdom
- 14:10 - 14:25 Optimal Use of IO Therapy in TNBC: Where are we in 2022?
Javier Cortes, Spain
- 14:25 - 14:40 Recent Advances in IO Therapy in Melanoma
Jeffrey Weber, USA
- 14:40 - 14:55 Recent Advances in IO Therapy in GI Malignancies
Kai-Keen Shiu, United Kingdom
- 14:55 - 15:25 Tumor Board: Challenging Cases in IO therapy in GI Malignancies
Moderator: Tobias Arkenau, United Kingdom
Panelist: Kai-Keen Shiu, United Kingdom | Bhawna Sirohi, India | Mohsen Mokhtar, Egypt | Nouri Bennini, UAE | Hassan Ghazal, UAE | Dalia ElShorbagy, UAE
- 15:25 - 15:45 Evolving Role of Immunotherapy in Advanced BTC - *Supported by AstraZeneca*
Deborah Mukherji, UAE
- 15:45 - 16:00 **Coffee Break**

SESSION 2

- Chairperson:** Faraz Khan, UAE | Hassan Ghazal, UAE
- 16:00 - 16:20 30 Years of Innovation & Commitment to Enhancing Patient Experience - Neulastim® Onpro® - *Supported by Kyowa Kirin*
Aref Chehal, UAE
- 16:20 - 16:35 Evolving Role of Neoadjuvant IO Therapy: Is this the Optimal Approach?
Giuseppe Curigliano, Italy
- 16:35 - 16:50 Biomarkers and IO Therapy: Is there a Perfect Biomarker?
Raghav Sundar, Singapore
- 16:50 - 17:20 **Panel Discussion:** How to handle side effects of IO Therapy: Challenging Cases in the Clinic
Moderator: Tobias Arkenau, United Kingdom
Panelist: Faraz Khan, UAE | Fathi Azribi, UAE | Aref Chehal, UAE | Ramanujam Singarachari, UAE | Emad Anwar Dawoud, UAE | Dalia ElShorbagy, UAE